^
Association details:
Biomarker:MSI-H/dMMR
Cancer:Colon Cancer
Regimen:FOLFOX (5-fluorouracil + leucovorin calcium + oxaliplatin)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Title:

Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Published date:
07/20/2020
Excerpt:
Recommendations: For High risk stage III colon cancer…with MSI or MSS…FOLFOX for 6 months and CAPOX for 6 months. For low risk stage III colon cancer...with MSI or MSS…FOLFOX for 6 months and CAPOX for 3 months (Fig-3).
DOI:
10.1016/j.annonc.2020.06.022